Biotechnology With its Vabysmo (faricimab) already approved in more than 50 markets including the USA and Europe for the treatment of wet, or neovascular, age-related macular degeneration (AMD), Swiss pharma giant Roche is now touting the benefits of the drug in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). 10 February 2023